Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0840
Source ID: NCT00395291
Associated Drug: Mk-0677
Title: Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00395291/results
Conditions: Chronic Kidney Disease|End Stage Renal Disease
Interventions: DRUG: MK-0677|DRUG: Placebo
Outcome Measures: Primary: Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the IGF-1 levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention | Secondary: Change in Acyl-Ghrelin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Acyl-Ghrelin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention.|Change in Leptin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Leptin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in Insulin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Insulin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in Des-Acyl Ghrelin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Des-Acyl Ghrelin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in TNF-alpha After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the TNF-alpha levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in CRPs After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the CRPs levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in IL-1 After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the IL-1 levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Changes in the Following Level: IL-6, Change in IL-6 after 30 days of intervention., After the subject has comleted their last visit|Change in IL-10 After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the IL-10 levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in Esterase After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Esterase levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in Adiponectin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Adiponectin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention|Change in Ghrelin After 30 Days of Intervention Compared to Baseline Level., Looking for a change in the Ghrelin levels after the subject has been on intervention for 30 days compared to baseline levels., Baseline and after 30 days of intervention
Sponsor/Collaborators: Sponsor: University of Virginia | Collaborators: National Institutes of Health (NIH)|Merck Sharp & Dohme LLC
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 49
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2006-08
Completion Date: 2010-05
Results First Posted: 2012-01-06
Last Update Posted: 2017-02-20
Locations: University of Virginia, Charlottesville, Virginia, 22908, United States
URL: https://clinicaltrials.gov/show/NCT00395291